Adenocarcinoma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2025-05-18
Clinical Trial Update: Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease [Phase 2]
A Phase 2 trial evaluating high-dose intravenous ascorbic acid in measurable solid tumors has been withdrawn, sponsored by Situs Cancer Rese…
CLINICAL_TRIALS withdrawal · 2022-12-05
Clinical Trial Update: Methadone for 'Adenocarcinopathic' Pain Treatment [Phase 3]
Phase 3 trial of methadone for cancer-related pain was withdrawn.
EMA withdrawal · 2022-05-20
EMA Withdrawn: Docetaxel Zentiva (previously Docetaxel Winthrop) (docetaxel) — Zentiva k.s.
The EMA has withdrawn Docetaxel Zentiva (docetaxel) from the market. The therapeutic areas formerly associated include head and neck neoplas…
EMA withdrawal · 2021-12-14
EMA Withdrawn: Docetaxel Teva (docetaxel) — Teva B.V.
The EMA has withdrawn Docetaxel Teva, an injectable chemotherapy containing docetaxel, from the European market.
CLINICAL_TRIALS withdrawal · 2017-06-26
Clinical Trial Update: School Response to Families Who Have Children With Cancer
The clinical trial has been withdrawn from the registry.
Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
CLINICAL_TRIALS withdrawal · 2017-02-07
Clinical Trial Update: MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases [Phase 2]
Phase 2 trial of MRI-guided High Intensity Focused Ultrasound (HIFU) with ThermoDox for palliation of painful bone metastases has been withd…
EMA withdrawal · 2015-03-12
EMA Lapsed: Docetaxel Mylan (docetaxel) — Mylan S.A.S.
EMA status shows Docetaxel Mylan has lapsed; related indications include head and neck neoplasms, non-small cell lung carcinoma, adenocarcin…
EMA withdrawal · 2010-03-26
EMA Application withdrawn: Docetaxel Mylan (docetaxel) — Mylan S.A.S.
Withdrawal of the EMA application for Docetaxel Mylan (docetaxel) by Mylan S.A.S., affecting multiple solid tumor indications including non-…